Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Insights into molecular mechanism of action of salan titanium(IV) complex with in vitro and in vivo anticancer activity.

Miller M, Braitbard O, Hochman J, Tshuva EY.

J Inorg Biochem. 2016 Oct;163:250-257. doi: 10.1016/j.jinorgbio.2016.04.007. Epub 2016 Apr 9.

PMID:
27090292
2.

Specific Design of Titanium(IV) Phenolato Chelates Yields Stable and Accessible, Effective and Selective Anticancer Agents.

Meker S, Braitbard O, Hall MD, Hochman J, Tshuva EY.

Chemistry. 2016 Jul 11;22(29):9986-95. doi: 10.1002/chem.201601389. Epub 2016 Jun 20.

PMID:
27320784
3.

A new immunization and treatment strategy for mouse mammary tumor virus (MMTV) associated cancers.

Braitbard O, Roniger M, Bar-Sinai A, Rajchman D, Gross T, Abramovitch H, La Ferla M, Franceschi S, Lessi F, Naccarato AG, Mazzanti CM, Bevilacqua G, Hochman J.

Oncotarget. 2016 Apr 19;7(16):21168-80. doi: 10.18632/oncotarget.7762.

4.

Highly Effective and Hydrolytically Stable Vanadium(V) Amino Phenolato Antitumor Agents.

Reytman L, Braitbard O, Hochman J, Tshuva EY.

Inorg Chem. 2016 Jan 19;55(2):610-8. doi: 10.1021/acs.inorgchem.5b02519. Epub 2015 Dec 23.

PMID:
26699515
5.

Highly Stable Tetra-Phenolato Titanium(IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity.

Meker S, Braitbard O, Margulis-Goshen K, Magdassi S, Hochman J, Tshuva EY.

Molecules. 2015 Oct 9;20(10):18526-38. doi: 10.3390/molecules201018526.

6.

Anti-proliferative activity of nano-formulated phenolato titanium(IV) complexes against cancer cells.

Meker S, Margulis-Goshen K, Weiss E, Braitbard O, Hochman J, Magdassi S, Tshuva EY.

ChemMedChem. 2014 Jun;9(6):1294-8. doi: 10.1002/cmdc.201400038. Epub 2014 Mar 26.

PMID:
24677761
7.

The signal peptide of mouse mammary tumor virus-env: a phosphoprotein tumor modulator.

Feldman D, Roniger M, Bar-Sinai A, Braitbard O, Natan C, Love DC, Hanover JA, Hochman J.

Mol Cancer Res. 2012 Aug;10(8):1077-86. doi: 10.1158/1541-7786.MCR-11-0581. Epub 2012 Jun 27.

8.

Reversing ABCB1-mediated multi-drug resistance from within cells using translocating immune conjugates.

Wellhöner H, Weiss A, Schulz A, Adermann K, Braitbard O, Bar-Sinai A, Hochman J.

J Drug Target. 2012 Jun;20(5):445-52. doi: 10.3109/1061186X.2012.685473.

PMID:
22577854
9.

Highly cytotoxic vanadium(V) complexes of salan ligands; insights on the role of hydrolysis.

Reytman L, Braitbard O, Tshuva EY.

Dalton Trans. 2012 May 7;41(17):5241-7. doi: 10.1039/c2dt11514j. Epub 2012 Mar 13.

PMID:
22415291
10.

Cytotoxic salan-titanium(IV) complexes: high activity toward a range of sensitive and drug-resistant cell lines, and mechanistic insights.

Manna CM, Braitbard O, Weiss E, Hochman J, Tshuva EY.

ChemMedChem. 2012 Apr;7(4):703-8. doi: 10.1002/cmdc.201100593. Epub 2012 Jan 20.

PMID:
22262543
11.

NEROFE--a novel human hormone-peptide with anti-cancer activity.

Sandler U, Devary O, Braitbard O, Ohana J, Kass G, Rubinstein AM, Friedman ZY, Devary Y.

J Exp Ther Oncol. 2010;8(4):327-39.

PMID:
21222365
12.

An ELISA-based procedure for assaying proteins in digests of human leukocytes and cell lines, using specifically selected peptides and appropriate antibodies.

Braitbard O, Bishara-Shieban J, Glickstein H, Kott-Gutkowski M, Pace U, Rund DG, Stein WD.

Proteome Sci. 2006 Jun 21;4:14.

13.

Competition between bound and free peptides in an ELISA-based procedure that assays peptides derived from protein digests.

Braitbard O, Glickstein H, Bishara-Shieban J, Pace U, Stein WD.

Proteome Sci. 2006 May 31;4:12.

Supplemental Content

Loading ...
Support Center